1. Home
  2. TNGX vs PFL Comparison

TNGX vs PFL Comparison

Compare TNGX & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • PFL
  • Stock Information
  • Founded
  • TNGX 2014
  • PFL 2003
  • Country
  • TNGX United States
  • PFL United States
  • Employees
  • TNGX N/A
  • PFL N/A
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • PFL Finance Companies
  • Sector
  • TNGX Health Care
  • PFL Finance
  • Exchange
  • TNGX Nasdaq
  • PFL Nasdaq
  • Market Cap
  • TNGX 351.2M
  • PFL 375.4M
  • IPO Year
  • TNGX N/A
  • PFL N/A
  • Fundamental
  • Price
  • TNGX $5.63
  • PFL $8.34
  • Analyst Decision
  • TNGX Strong Buy
  • PFL
  • Analyst Count
  • TNGX 6
  • PFL 0
  • Target Price
  • TNGX $12.20
  • PFL N/A
  • AVG Volume (30 Days)
  • TNGX 3.4M
  • PFL 113.7K
  • Earning Date
  • TNGX 08-06-2025
  • PFL 01-01-0001
  • Dividend Yield
  • TNGX N/A
  • PFL 11.53%
  • EPS Growth
  • TNGX N/A
  • PFL N/A
  • EPS
  • TNGX N/A
  • PFL N/A
  • Revenue
  • TNGX $40,990,000.00
  • PFL N/A
  • Revenue This Year
  • TNGX N/A
  • PFL N/A
  • Revenue Next Year
  • TNGX N/A
  • PFL N/A
  • P/E Ratio
  • TNGX N/A
  • PFL N/A
  • Revenue Growth
  • TNGX 10.09
  • PFL N/A
  • 52 Week Low
  • TNGX $1.03
  • PFL $6.98
  • 52 Week High
  • TNGX $12.02
  • PFL $8.62
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 77.32
  • PFL 55.79
  • Support Level
  • TNGX $4.80
  • PFL $8.30
  • Resistance Level
  • TNGX $5.63
  • PFL $8.35
  • Average True Range (ATR)
  • TNGX 0.52
  • PFL 0.05
  • MACD
  • TNGX -0.03
  • PFL 0.00
  • Stochastic Oscillator
  • TNGX 83.33
  • PFL 71.43

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest

PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.

Share on Social Networks: